A detailed history of China Universal Asset Management Co., Ltd. transactions in Geron Corp stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 69,683 shares of GERN stock, worth $309,392. This represents 0.04% of its overall portfolio holdings.

Number of Shares
69,683
Previous 104,929 33.59%
Holding current value
$309,392
Previous $346,000 14.74%
% of portfolio
0.04%
Previous 0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

SELL
$3.1 - $5.09 $109,262 - $179,402
-35,246 Reduced 33.59%
69,683 $295,000
Q1 2024

Apr 29, 2024

BUY
$1.75 - $3.44 $73,690 - $144,854
42,109 Added 67.03%
104,929 $346,000
Q4 2023

May 21, 2024

SELL
$1.74 - $2.31 $73,269 - $97,271
-42,109 Reduced 40.13%
62,820 $132,000
Q4 2023

Jan 23, 2024

BUY
$1.74 - $2.31 $85,945 - $114,100
49,394 Added 367.9%
62,820 $133,000
Q3 2023

May 21, 2024

BUY
$2.11 - $3.28 $14,257 - $22,162
6,757 Added 101.32%
13,426 $28,000
Q3 2023

Oct 30, 2023

BUY
$2.11 - $3.28 $14,257 - $22,162
6,757 Added 101.32%
13,426 $28,000
Q2 2023

May 21, 2024

BUY
$1.97 - $3.69 $1,471 - $2,756
747 Added 12.61%
6,669 $21,000
Q2 2023

Jul 27, 2023

BUY
$1.97 - $3.69 $1,471 - $2,756
747 Added 12.61%
6,669 $21,000
Q1 2023

May 21, 2024

BUY
$2.14 - $3.4 $4,384 - $6,966
2,049 Added 52.9%
5,922 $12,000
Q1 2023

Apr 27, 2023

BUY
$2.14 - $3.4 $4,384 - $6,966
2,049 Added 52.9%
5,922 $13,000
Q4 2022

May 21, 2024

SELL
$2.03 - $2.42 $205,143 - $244,555
-101,056 Reduced 96.31%
3,873 $9,000
Q4 2022

Jan 31, 2023

BUY
$2.03 - $2.42 $680 - $810
335 Added 9.47%
3,873 $9,000
Q3 2022

Oct 21, 2022

BUY
$1.67 - $2.94 $5,908 - $10,401
3,538 New
3,538 $8,000

Others Institutions Holding GERN

About GERON CORP


  • Ticker GERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 377,819,008
  • Market Cap $1.68B
  • Description
  • Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...
More about GERN
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.